At Nephron Research, our mission is to be essential to our clients’ investment process.
As the market’s leading independent healthcare equity research provider, we strive to separate market noise from the insights that are essential to the investment process.
Nephron’s primary differentiators lie in our research teams and their approach to equity research. The deep experience and insight of our analysts as well as an intense drive to serve a discerning client base sets us apart. With the sole focus of creating value for clients, Nephron can provide a depth of coverage, breadth of access, and consultative services that traditional models lack.
Delivered via an independent and unbiased subscription-only model, Nephron is directly aligned with our client’s interests and investment processes
Meet The Team
At Nephron Research, our experience and connectivity drive deep research products which is supplemented by hyper-relevant corporate access
Process Drives We tackle the most important debates, react quickly, and provide leading perspective
NEPHRON RESEARCH COVID-19 Daily Tracker: June 3, 2020; Hot Spots - States
Download
HMOs and Hospitals: 20 Questions and 20 Answers to Quantify the COVID19 Impact
Download
A Closer Look: COVID-19 Script Declines Represent an Acute, Not Chronic, Problem
DownloadNephron Research Curates Dozens of Events Each Year Designed for Maximum Impact to Client Investment Process
We were joined by Dr. Niall Lennon & Dr. Stacey Gabriel for a "virtual tour" with two leading genomics researchers.
We were joined by a diverse set of Biopharma, PBM and Payor leaders and innovators for a series of panels focused on the evolution of transparent PBM models with an eye to recent development and collaborations.
Our event event featured a diverse set of opinions from the leading innovators across public and private companies. We were joined by leading experts to address the key debates around clinical data, reimbursement and regulatory pathways to commercialization. Participating companies included Exact Sciences (EXAS), Guardant Health (GH), Natera (NTRA) and Biological Dynamics (private).
Our independent model and deep healthcare and investment expertise allows us to deliver a full suite of bespoke
and consultative services to investment firms and market participants.
